Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Withdrawn before enrolling
Conditions studied: ST-elevation Myocardial Infarction, Acute Myocardial Infarction
In brief
The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction in a large tertiary referral center. It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is superior to unfractionated heparin alone or bivalirudin alone. Additionally, after propensity matching this superiority remains.
Key facts
- Study ID
- NCT01991366
- Run by
- Medstar Health Research Institute
- People needed
- 0
- Starts
- 2013-10-01
- Expected to finish
- 2021-06-01
- Last updated by the study team
- 2021-07-02
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Underwent Percutaneous Coronary Intervention at Washington Hospital Center since September 2000
- Either received eptifibatide pre-or during PCI or have received no eptifibatide.
You may not qualify if…
- Patients who received a thrombolytic prior to Percutaneous Coronary Intervention.
Where it is running
- Washington Hospital Center — Washington D.C., District of Columbia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.